Abstract
In studies conducted on largely treatment naive patients in their first episode of psychosis, we have found that treatment outcome is quite good and that most patients recover or at least achieve a substantial degree of symptom remission. However, over the course of their illness and in the context of subsequent psychotic episodes, they may experience some decrease in their treatment response from illness progression. In addition, the heterogeneity of treatment outcome is associated with specific clinical (gender, primary negative symptoms of the deficit state, duration of psychosis) and biological variables (pHVA, ventricular volume). It is unclear whether these variables represent aspects of discrete subtypes of schizophrenia or dimensional measures of pathology within the broad context of a unitary disease entity.
Author information
Authors and Affiliations
Additional information
This article was presented at the integrated symposium “A New Understanding: Neurological Basis and Long-Term Outcome of Schizophrenia” chaired by Herbert Y. Meltzer and Leif H. Lindström at the CINP Congress, June 28, 1994, in Washington, DC.
Rights and permissions
About this article
Cite this article
Lieberman, J., Alvir, J., Koreen, A. et al. Psychobiologic Correlates of Treatment Response in Schizophrenia. Neuropsychopharmacol 14 (Suppl 1), 13–21 (1996). https://doi.org/10.1016/0893-133X(95)00200-W
Published:
Issue Date:
DOI: https://doi.org/10.1016/0893-133X(95)00200-W
Keywords
- Schizophrenia
- Antipsychotic Drugs
- Outcome
- Brain morphology
- Dopamine
- Deterioration
This article is cited by
-
Reduced erythrocyte membrane polyunsaturated fatty acid levels indicate diminished treatment response in patients with multi- versus first-episode schizophrenia
Schizophrenia (2022)
-
Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
Annals of General Psychiatry (2020)
-
Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm
CNS Drugs (2020)
-
Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia
Scientific Reports (2020)
-
Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia
Neuropsychopharmacology (2019)
